We are upgrading the repository! A content freeze is in effect until November 22nd, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Preformulation studies of melanotan-II
| dc.contributor.advisor | Blanchard, James | en_US |
| dc.contributor.author | Lan, En-Ling, 1964- | |
| dc.creator | Lan, En-Ling, 1964- | en_US |
| dc.date.accessioned | 2013-05-16T09:31:14Z | en |
| dc.date.available | 2013-05-16T09:31:14Z | en |
| dc.date.issued | 1992 | en_US |
| dc.identifier.uri | http://hdl.handle.net/10150/291574 | en |
| dc.description.abstract | Melanotan-II (MT-II) is a cyclic heptapeptide analogue of α-MSH (α-melanocyte stimulating hormone) which tans the skin rapidly and is currently being evaluated for the prevention of sunlight-induced skin cancers. In these preformulation studies, the degradation of MT-II followed apparent first-order kinetics. The degradation rate increased as the temperature or phosphate buffer concentration were increased. The pH-rate profile of MT-II degradation showed that MT-II was most stable at approximately pH 5. The degradation of MT-II was not affected by ionic strength. The pKa1 and pKa2 were estimated to be 6.53 and 11.74, respectively. The partition coefficient was studied at various pH values. The Δ log PC at pH 7.35 was 1.05 which indicated that MT-II could pass the intestinal membrane relatively easily. The preformulation data presented here can be used to help develop an appropriate dosage form for MT-II. | |
| dc.language.iso | en_US | en_US |
| dc.publisher | The University of Arizona. | en_US |
| dc.rights | Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. | en_US |
| dc.subject | Chemistry, Pharmaceutical. | en_US |
| dc.title | Preformulation studies of melanotan-II | en_US |
| dc.type | text | en_US |
| dc.type | Thesis-Reproduction (electronic) | en_US |
| thesis.degree.grantor | University of Arizona | en_US |
| thesis.degree.level | masters | en_US |
| dc.identifier.proquest | 1350780 | en_US |
| thesis.degree.discipline | Graduate College | en_US |
| thesis.degree.discipline | Pharmaceutical Sciences | en_US |
| thesis.degree.name | M.S. | en_US |
| dc.identifier.bibrecord | .b2546971x | en_US |
| refterms.dateFOA | 2018-08-30T00:57:24Z | |
| html.description.abstract | Melanotan-II (MT-II) is a cyclic heptapeptide analogue of α-MSH (α-melanocyte stimulating hormone) which tans the skin rapidly and is currently being evaluated for the prevention of sunlight-induced skin cancers. In these preformulation studies, the degradation of MT-II followed apparent first-order kinetics. The degradation rate increased as the temperature or phosphate buffer concentration were increased. The pH-rate profile of MT-II degradation showed that MT-II was most stable at approximately pH 5. The degradation of MT-II was not affected by ionic strength. The pKa1 and pKa2 were estimated to be 6.53 and 11.74, respectively. The partition coefficient was studied at various pH values. The Δ log PC at pH 7.35 was 1.05 which indicated that MT-II could pass the intestinal membrane relatively easily. The preformulation data presented here can be used to help develop an appropriate dosage form for MT-II. |
